MET and head and neck squamous cell carcinoma: Another Phase Ib/II trial exploring the safety and efficacy of capmatinib treatment with cetuximab, an anti-EGFR antibody, in HNSCC and metastatic colorectal cancers positive for c-Met has recently been suspended for unknown reasons (NCT02205398).